Document:

EX-10.15

 Exhibit 10.15 

 
 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT 

This Amended and Restated Executive Employment Agreement (this “Agreement”) is entered into between Allovir, Inc.,
f/k/a ViraCyte Inc., a Delaware corporation (“Company”) and Vikas Sinha (“Employee”). This Agreement is effective as of the later of (i) the date the Agreement becomes fully executed by the
parties; or (ii) ten (10) business days after the Company provides Employee with the Restrictive Covenants Agreement (as defined below) (the “Effective Date”). 

WHEREAS, the Company and Employee are parties to a Consulting and Executive Employment Agreement entered into on December 3, 2018 (the
“Prior Agreement”); 
 WHEREAS, the Company and Employee desire to fully supersede and replace the Prior Agreement
with this Agreement; provided that the Company and Employee desire to preserve Exhibit A to the Prior Agreement, the Restricted Stock Agreement, and any exhibits and/or attachments thereto, and Exhibit B to the Prior Agreement, the Employee
Invention Assignment and Confidentiality Agreement, and any exhibits and/or attachments thereto, (with Exhibit A and Exhibit B to the Prior Agreement referred to collectively as the “Prior Exhibits”) and acknowledge and agree
that such Prior Exhibits (and any exhibits and/or attachments thereto) shall remain in full force and effect both during and after Employee’s employment relationship with the Company; 

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby confirmed, the Company and Employee agree as follows: 

1. Position and Duties. The Company will continue to employ Employee as the President and Chief Financial Officer
of the Company. Employee will report to the Chief Executive Officer of the Company (the “CEO”) and will render such business and professional services in the performance of his duties, consistent with Employee’s
position, as shall reasonably be assigned to him by the CEO or the Company’s Board of Directors (the “Board”). 

2. Board Service. Employee will continue to serve as a member of the Board and shall be re-elected so long as Employee is employed by the Company in the capacity of Chief Financial Officer. Employee may be removed from the Board in accordance with applicable law and the Company’s bylaws. If
Employee ceases to be employed by the Company, Employee will resign from all Board positions at the request of the Board. 

3. Service to the Company. Except as otherwise specified herein, Employee will be expected to devote his full
working time and attention to the business of the Company, and will not render services to any other business without the prior approval of the Board or, directly or indirectly, engage or participate in any business that is competitive in any manner
with the business of the Company; provided, however, that Employee may continue to serve on the boards of directors and advisory boards on which he presently serves, all of which have been disclosed to the Company, and may serve on additional
boards (whether advisory or boards of directors) with the prior approval of the Board, not to be unreasonably withheld. The Company acknowledges that Employee is a party to an employment agreement with ElevateBio Management, Inc.,
(“ElevateBio”) and will devote a portion of his working time to ElevateBio and its subsidiaries and affiliates. Employee will also be expected to comply with and be bound by the Company’s operating policies, procedures and practices
that are from time to time in effect during the term of his employment and are provided to Employee. 

  
 1 

 4. At-Will Employment.
Employee and the Company understand and acknowledge that Employee’s employment with the Company constitutes “at-will” employment, and the employment relationship may be terminated at any time,
with or without cause and with or without notice. 
 5. Compensation and Benefits. 

5.1 Base Salary. The Company shall pay the Employee an annual base salary of $400,000 (as adjusted from time to time in
accordance with the terms hereof, the “Base Salary”), payable in accordance with the Company’s normal payroll practices. The Board shall periodically review (at least annually) Employee’s Base Salary, provided that
any changes thereto shall be determined by the Board in its sole and absolute discretion. 
 5.2 Corporate Objectives
Bonus. Employee will be eligible to receive an annual cash bonus with a target bonus opportunity of 40% of Employee’s then current Base Salary (the “Target Annual Bonus”), upon the achievement of annual corporate
performance goals determined by the Board. Annual corporate performance goals shall be determined no later than the end of January of the performance year, which generally shall be coincident with the calendar year. The Board, at its sole
discretion, may increase Employee’s Annual Bonus or award an additional bonus to the Employee for extraordinary service to the Company. To receive payment of any bonus Employee must be employed by the Company at the time bonuses are paid. 

5.3 Employee Benefits. Employee shall be eligible to participate in all employee benefit plans and arrangements,
including, but not limited to, medical, dental, vision and long-term disability insurance benefits and arrangements, as are made available by the Company to its other senior executives, subject to the terms and conditions thereof. 

5.4 Vacation. Employee will be entitled to paid vacation (in addition to Company holidays) pursuant to the terms of the
Company’s vacation policy as may exist from time to time. 
 6. Equity Matters. All equity awards Employee
received or may be eligible to receive from the Company shall be governed by the terms of such awards’ applicable restrictive stock agreements and documents, including, but not limited to, the 2019 AlloVir (formerly ViraCyte) Stock Plan,
(collectively, and as any may be amended, the “Equity Documents”); notwithstanding the provisions in the Equity Documents, in the event of a Sale Event as that term is defined in the 2019 AlloVir (formerly ViraCyte) Stock
Plan all unvested equity shall vest upon the closing of such a Sale Event. 

  
 2 

 7. Expenses. The Company will, in accordance
with applicable Company policies and guidelines, reimburse Employee for all reasonable and necessary expenses incurred by Employee in connection with his performance of services on behalf of the Company. 

8. Inventions and Proprietary Information, Non-Competition. In exchange
for, among other things, a one-time, lump-sum payment of $5,000, which Employee acknowledges and agrees is fair and reasonable consideration that is independent from the
continuation of employment with the Company, Employee agrees to the terms of the Restrictive Covenants Agreement attached to this Agreement as Exhibit A (the “Restrictive Covenants Agreement”), which is hereby
incorporated by reference into this Agreement. Employee acknowledges and understands that he has been advised by the Company that he has the right to consult with counsel prior to signing the Restrictive Covenants Agreement. Employee further
acknowledges and agrees that Employee received the Restrictive Covenants Agreement at least ten (10) business days before the Restrictive Covenants Agreement is to become effective. 

9. Definitions. 

9.1 Cause. For purposes of this Agreement, “Cause” means the occurrence of any of the following
after the Effective Date (i) Employee’s persistent failure to carry out any material lawful duties of Employee or any lawful directions of the CEO reasonably consistent with Employee’s duties; provided, however, that Employee has been
given reasonable notice of the specific failure and an opportunity to correct such failure within thirty (30) business days from the date of the notice; (ii) Employee’s conviction of or plea of nolo contendere to a felony, which has
had or will have a detrimental effect on the Company’s reputation or business, (iii) Employee engaging in an act of gross negligence or willful misconduct in the performance of his employment obligations and duties,
(iv) Employee’s commission of an act of fraud against the Company or willful misappropriation of property belonging to the Company; (v) Employee engaging in any other willful misconduct that has caused or will cause material harm to
the Company’s reputation or business; or (vi) Employee’s material breach of the Restrictive Covenants Agreement or the Prior Exhibits. No act or failure to act will be considered “willful” unless Employee has acted, or
failed to act, with a lack of good faith and with a lack of reasonable belief that Employee’s action or failure to act was in the best interest of the Company or any of its affiliates. 

9.2 Disability. For purposes of this Agreement “Disability” shall have that meaning set forth in
Section 22(e)(3) of the Internal Revenue Code of 1986, as amended (the “Code”). 
 9.3 Good
Reason. For purposes of this Agreement, “Good Reason” means any of the following actions that have been taken by the Company without Employee’s written consent, provided that (a) the Company receives, within
ninety (60) days following Employee’s knowledge of the occurrence of any of the conditions or events set forth in clauses (i) through (v) below, written notice from Employee specifying the specific basis for Employee’s belief
that Employee is entitled to terminate employment for Good Reason, (b) the Company fails to cure the condition or event constituting Good Reason within thirty (30) days after receipt of such written notice thereof, and (c) Employee
terminates employment within thirty (30) days following expiration of such cure period: 

  
 3 

 (i) A material diminution in Employee’s responsibilities, authority, or
duties; 
 (ii) A material diminution in Employee’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company; 

(iii) A material change in the geographic location at which Employee provides services to the Company, such that there is an
increase of at least thirty (30) miles of driving distance to such location from the Executive’s principal place of residence as of such change; or 

(iv) A material breach of this Agreement by the Company. 

10. Effect of Separation from Service. For purposes of this Agreement, no payment will be made to Employee upon
termination of Employee’s employment unless such termination constitutes a “separation from service” within the meaning of Section 409A of the Code, and
Section 1.409A-1(h) of the regulations promulgated thereunder. 
 10.1
Separation for Cause, Death, Disability or Voluntary Separation from Service. In the event of Employee’s separation from service from the Company for Cause or in the event of Employee’s death, Disability or voluntary separation from
service at any time and for any reason, Employee or his estate will be paid only (i) any earned but unpaid Base Salary, (ii) other unpaid vested amounts or benefits under the compensation, incentive and benefit plans of the Company in
which Employee participates (including accrued vacation earned through his separation from service), and (iii) reimbursement for all reasonable and necessary expenses incurred by Employee in connection with his performance of services on behalf
of the Company in accordance with applicable Company policies and guidelines, in each case as of the effective date of such separation from service (the “Accrued Compensation”). In the event of Employee’s death or
Disability, any unvested stock option held by Employee shall be accelerated in vesting in an amount equal to (i) twenty five percent (25%) plus (ii) five percent (5%) for each year of service to the Company of the total number of shares
covered by the option. Employee or his estate will be allowed to exercise his vested stock options to purchase the Company’s common stock, if any, during the time period set forth in, and in accordance with, the Company’s 2018 Equity
Incentive Plan and governing stock option agreements. 
 10.2 Separation from Service without Cause or for Good
Reason. In the event of Employee’s separation from service from the Company without Cause or for Good Reason, and provided that Employee delivers to the Company a signed separation agreement and release in a form and manner satisfactory to
the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities, a reaffirmation of all of the Employee’s Continuing Obligations (as defined below), and, in the
Company’s sole discretion, a one-year post-employment non-competition restriction in a form substantially similar to the
Non-Competition Restriction (as defined in the Restrictive Covenants Agreement attached hereto as Exhibit A) (the “Separation Agreement and Release”), and (ii) the Separation
Agreement and Release becoming irrevocable all within sixty (60) days following Employee’s separation from service (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven (7) business
day revocation period, then, in addition to the Accrued Compensation, Employee shall be entitled to the following: 

  
 4 

 (i) A lump sum payment equal to (a) eighteen (18) months so long as the
Company is a privately-owned company or (b) twenty-four (24) months if the Company becomes a publicly-traded company on the NASDAQ or NYSE (in either case, the “Severance Period”) of the Employee’s then current
Base Salary payable on the sixty-first (61st) day following the date of Employee’s separation from service; 
 (ii) A
lump sum payment for Target Annual Bonus payable on the sixty-first (61st) day following the date of Employee’s separation from service (collectively, with the payment provided for in Section 10.2(i), the “Severance
Amount”); 
 (iii) Notwithstanding in the foregoing, in the event Employee is entitled to any payments pursuant
to the Restrictive Covenants Agreement, the Severance Amount will be reduced by the amount Employee is paid pursuant to the Restrictive Covenants Agreement; 

(iv) Provided Employee timely elects to continue health coverage under the Consolidated Omnibus Budget Reconciliation Act of
1985, as amended (“COBRA”), reimbursement for any monthly COBRA premium payments made by Employee for Employee and his eligible dependents until the earliest of (a) the expiration of the Severance Period;
(b) Employee’s eligibility for group medical plan benefits under any other employer’s group medical plan; or (c) the cessation of Employee’s continuation rights under COBRA; provided, however, if the Company determines that
it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company
shall convert such payments to payroll payments directly to Employee for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the
Company’s regular payroll dates. For the avoidance of doubt, the taxable payments described above may be used for any purpose, including, but not limited to, continuation coverage under COBRA; and, 

(v) Notwithstanding the provisions of Section 6, all unvested and earned equity awards held by Employee at the time of
such separation from service shall accelerate in vesting and, as applicable, become fully exercisable and all stock options will remain exercisable thereafter in accordance with the terms of the applicable award agreement.  
 10.3 Parachute Payments. In the event that any payments or
benefits provided for in this Agreement or otherwise payable to Employee (collectively, the “Payments”) (i) constitute “parachute payments” within the meaning of Section 280G of the Code and
(ii) but for this Section, would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full, or (ii) as to such lesser amount which would result in no portion of the
Payments being subject to the excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in
the receipt by Employee on an after-tax basis, of the greatest amount of Payments, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. Any
reduction to the Payments required under this Section shall be made by the Company in its reasonable discretion in the following order and in a manner intended to comply with Section 409A of the Code (as determined by the Company): (i) payments
that are payable in cash that are valued at full value under Treasury Regulation Section 1.280G-1, Q&A 24(a) will be reduced (if necessary, to zero), with amounts that are payable last reduced first;
(ii) payments and benefits due in respect of any equity valued at full value under Treasury Regulation Section 1.280G-1, Q&A 24(a), with the highest values reduced first (as such values are
determined under Treasury Regulation Section 1.280G-1, Q&A 24), will next be reduced; (iii) payments that are payable in cash that are valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24, with amounts that are payable last reduced first, will next be reduced; (iv) payments and benefits due in respect of any equity valued at less than full value under Treasury
Regulation Section 1.280G-1, Q&A 24, with the highest values reduced first (as such values are determined under Treasury Regulation Section 1.280G-1,
Q&A 24), will next be reduced; and (v) all other non-cash benefits not otherwise described in clauses (ii) or (iv) hereof will be next reduced pro-rata.
Any reductions made pursuant to each of clauses (i)-(v) of the immediately preceding sentence will be made in the following manner: first, a pro-rata reduction of cash payment and payments and benefits due in
respect of any equity not subject to Section 409A of the Code, and second, a pro-rata reduction of cash payments and payments and benefits due in respect of any equity subject to Section 409A of the
Code as deferred compensation. Unless the Company and Employee otherwise agree in writing, any determinations required under this Section shall be made in writing by the Company’s independent public accountants (the
“Accountants”), whose determinations shall be conclusive and binding upon Employee and the Company for all purposes. The Company shall cause the Accountants to provide its determinations and any supporting calculations with
respect to Employee to the Company and Employee. For purposes of making the calculations required by this Section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith
interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination
under this Section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section. 

  
 5 

 11. Miscellaneous. 

11.1 Arbitration. Employee and the Company agree to submit to mandatory binding arbitration, in New York, New York, any
and all claims arising out of or related to this Agreement and Employee’s employment with the Company and the termination thereof, except that each party may, at its or his option, seek injunctive relief in court related to the improper use,
disclosure or misappropriation of a party’s proprietary, confidential or trade secret information. EMPLOYEE AND THE COMPANY HEREBY WAIVE ANY RIGHTS TO TRIAL BY JURY IN REGARD TO SUCH CLAIMS. This Agreement to arbitrate does not restrict
Employee’s right to file administrative claims Employee may bring before any government agency where, as a matter of law, the parties may not restrict Employee’s ability to file such claims (including, but not limited to, the National
Labor Relations Board, the Equal Employment Opportunity Commission and the Department of Labor). However, Employee and the Company agree that, to the fullest extent permitted by law, arbitration shall be the exclusive remedy for the subject matter
of such administrative claims. The arbitration shall be conducted through JAMS before a single neutral arbitrator, in accordance with the JAMS employment arbitration rules then in effect. The arbitrator shall issue a written decision that contains
the essential findings and conclusions on which the decision is based. 

  
 6 

 11.2 Indemnification. The Company shall indemnify Employee with
respect to activities in connection with his employment hereunder to the fullest extent provided in the Company’s bylaws. Employee will be named as an insured on the director and officer liability insurance policy currently maintained, or as
may be maintained by the Company from time to time, and, in addition, Employee will enter into the form of indemnification agreement provided to other similarly situated executive officers and directors of the Company. 

11.3 Section 409A. To the extent (i) any payments or benefits to which Employee becomes entitled
under this Agreement, or under any agreement or plan referenced herein, in connection with Employee’s termination of employment with the Company constitute deferred compensation subject to Section 409A of the Code and (ii) Employee is
deemed at the time of such termination of employment to be a “specified employee” under Section 409A of the Code, then such payments shall not be made or commence until the earliest of (a) the expiration of the six
(6)-month period measured from the date of Employee’s “separation from service” (as such term is at the time defined in Treasury Regulations under Section 409A of the Code) from the Company; or (b) the date of
Employee’s death following such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to Employee, including (without limitation) the additional twenty
percent (20%) tax for which Employee would otherwise be liable under Section 409A(a)(1)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable deferral period, any payments which would have otherwise been made
during that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to Employee or Employee’s beneficiary in one lump sum (without interest). Any termination of Employee’s employment is intended
to constitute a “separation from service” and will be determined consistent with the rules relating to a “separation from service” as such term is defined in Treasury Regulation Section 1.409A-1. It is intended that each installment of the payments provided hereunder constitute separate “payments” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). It is further intended that payments hereunder satisfy, to the greatest extent possible, the exemption from the application of Section 409A of the Code (and any state law of
similar effect) provided under Treasury Regulation Section 1.409A-1(b)(4) (as a “short-term deferral”). To the extent that any provision of this Agreement is ambiguous as to its
compliance with Section 409A of the Code, the provision will be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Except as otherwise expressly provided herein, to the extent any expense
reimbursement or the provision of any in-kind benefit under this Agreement is determined to be subject to Section 409A of the Code, the amount of any such expenses eligible for reimbursement, or the
provision of any in-kind benefit, in one calendar year shall not affect the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to
medical expenses), in no event shall any expenses be reimbursed after the last day of the calendar year following the calendar year in which Employee incurred such expenses, and in no event shall any right to reimbursement or the provision of any in-kind benefit be subject to liquidation or exchange for another benefit. 

  
 7 

 11.4 Severability. If any provision of this Agreement shall be found
by any arbitrator or court of competent jurisdiction to be invalid or unenforceable, then the parties hereby waive such provision to the extent of its invalidity or unenforceability and agree that all other provisions in this Agreement shall
continue in full force and effect. 
 11.5 No Waiver. The failure by either party at any time to require performance
or compliance by the other of any of its obligations or agreements shall in no way affect the right to require such performance or compliance at any time thereafter. The waiver by either party of a breach of any provision hereof shall not be taken
or held to be a waiver of any preceding or succeeding breach of such provision or as a waiver of the provision itself. No waiver of any kind shall be effective or binding, unless it is in writing and is signed by the party against whom such waiver
is sought to be enforced. 
 11.6 Assignment. This Agreement and all rights hereunder are personal to Employee and may
not be transferred or assigned by Employee at any time. The Company may assign its rights, together with its obligations hereunder, to any purchaser of all or substantially all of its business and assets, provided, however, that any such assignee
assumes the Company’s obligations hereunder. 
 11.7 Withholding. All sums payable to Employee hereunder shall be
in United States Dollars and shall be reduced by all federal, state, local and other withholding and similar taxes and payments required by applicable law. 

11.8 Continuing Obligations. For purposes of this Agreement, the obligations that arise in the Restrictive Covenants
Agreement, the Prior Exhibits, the Equity Documents, and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing
Obligations.” 
 11.9 Amendment. The parties understand and agree that this Agreement may not be amended,
modified or waived, in whole or in part, except in a writing executed by Employee and the Company. 
 11.10 Notices.
All notices, if any, and all other communications, if any, required or permitted under this Agreement shall be in writing and hand delivered, sent via facsimile, sent by registered first class mail, postage
pre-paid, or sent by nationally recognized express courier service. Such notices and other communications shall be effective upon receipt if hand delivered or sent via facsimile, five (5) days after
mailing if sent by mail, and one (l) day after dispatch if sent by express courier, to the following addresses, or such other addresses as any party shall notify the other parties: 

  
 8 

					
	       	 	If to the Company:	  	 Allovir, Inc.
 139 Main St., Suite
500
 Cambridge, MA 02142
 Attention: General
Counsel

			
		 	If to Employee:	  	The last address on file in the Company’s records.

 11.11 Binding Nature. This Agreement shall be binding upon, and inure to the benefit
of, the successors and personal representatives of the respective parties hereto. 
 11.12 Counterparts. This
Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which, taken together, constitute one and the same agreement. 

11.13 Governing Law. This Agreement and the rights and obligations of the parties hereto shall be construed in
accordance with the laws of the State of Delaware, without giving effect to the principles of conflict of laws. 
 11.14
Attorneys’ Fees. In the event of any claim, demand or suit arising out of or with respect to this Agreement, the prevailing party shall be entitled to reasonable costs and attorneys’ fees, including any such costs and fees upon
appeal. 
 11.15 Entire Agreement. This Agreement (and the exhibit(s) hereto, including but not limited to the
Restrictive Covenants Agreement) together with the Equity Documents, as amended, and the Prior Exhibits (and any exhibits and/or attachments thereto) constitute the entire and only agreement and understanding between the parties relating to
Employee’s employment with Company. Subject to the foregoing, this Agreement supersedes and cancels any and all previous contracts, arrangements or understandings with respect to
Employee’s employment. 
 IN WITNESS WHEREOF, the Company and Employee have executed this Amended and Restated Executive Employment
Agreement as of the date first above written. 
  

									
	ALLOVIR, INC.	 		 	Vikas Sinha
			
	 /s/ David Hallal
	 		 	 /s/ Vikas Sinha

			
	 Print Name: David Hallal
	 		 	 Print Name: Vikas Sinha

				
	Title: Chief Executive Officer	 		 	Address:	 	
					
	Date:	 	 10/2/2019
	 		 	Date:	 	 10/2/2019

  
 9 

 EXHIBIT A 

EMPLOYEE RESTRICTIVE COVENANTS AGREEMENT 

  
 10 

 EMPLOYEE RESTRICTIVE COVENANTS AGREEMENT 

In exchange for, among other things, a one-time, lump-sum
payment of $5,000, which Employee (as defined below) acknowledges and agrees is fair and reasonable consideration that is independent from the continuation of employment with the Company, Vikas Sinha (“Employee”) with Allovir, Inc., f/k/a
ViraCyte, Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”), enter into this Restrictive Covenants Agreement (this “Agreement”), and hereby agree to the following: 

 

	1.	 Proprietary Information. 

(a) Company Information. Employee agrees at all times during the term of Employee’s employment and thereafter,
to hold in strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any person, firm or corporation without written authorization of the Board of Directors of the Company, any Proprietary Information of the
Company, except under a non-disclosure agreement duly authorized and executed by the Company. Employee understands that “Proprietary Information” means any
non-public information regarding or relating to the Company or its products including: (1) the actual or anticipated business or research and development of the Company, technical data, trade secrets or know-how, including, but not limited to, research, product plans or other information regarding the Company’s products or services and markets therefore; (2) research, clinical or other trials,
developments, inventions, processes, formulas, technology, designs, drawings, engineering, software, hardware configuration information, marketing, finances or other business information; (3) customer lists and customers (including, but not
limited to, customers of the Company on whom Employee called or with whom Employee became acquainted during the term of Employee’s employment); (4) the identity, skills and compensation of employees, consultants, or contractors;
(5) policies and procedures of the Company; (6) anything related to Company Inventions (as defined herein); and (7) Third Party Information (as defined herein). Employee further understands that Proprietary Information does not
include any of the foregoing items which have become publicly known and made generally available through no wrongful act of the Employee or of others who were under confidentiality obligations as to the item or items involved or improvements or new
versions thereof. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), Employee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is
made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or
other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, notwithstanding the foregoing, Employee shall not be prohibited from disclosing Proprietary Information to a government agency as a whistleblower.

 (b) Third Party Information. Employee recognizes that the Company has received and in the future will receive
from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes (“Third Party Information”).
Employee agrees to hold all Third Party Information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out Employee’s work for the Company consistent with the
Company’s agreement with such third party. 

  
 1 

	2.	 Inventions. 

(a) Inventions Retained and Licensed. Employee has attached hereto, as Exhibit 1, a list describing all
inventions, original works of authorship, developments, improvements, and trade secrets which were made by Employee prior to Employee’s employment with the Company (collectively referred to as “Prior Inventions”), which belong to
Employee, which relate to the Company’s proposed business, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, Employee represents that there are no such Prior Inventions.
If in the course of Employee’s employment with the Company, Employee incorporates into a Company product, process or service a Prior Invention owned by Employee or in which Employee has an interest, Employee hereby grants to the Company a
nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Invention as part of or in connection with such product, process or
service, and to practice any method related thereto. 
 (b) Assignment of Inventions. Employee agrees that
Employee will promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby assign (or, for future inventions, agree to assign) to the Company, or its designee, all Employee’s
right, title, and interest in and to any and all inventions, original works of authorship, writings, developments, concepts, improvements, designs, discoveries, ideas, processes, formulas, data, trademarks or trade secrets, whether or not patentable
or registrable under copyright or similar laws, which Employee may solely or jointly conceive or develop or reduce to practice within the scope of Employee’s employment, or cause to be conceived or developed or reduced to practice, during the
period of time Employee is employed by the Company (collectively referred to as “Inventions”), except as provided in Section 2(f) below. Employee agrees that Company will exclusively own all work product that is made by
Employee (solely or jointly with others) within the scope of Employee’s employment. Employee further acknowledges that all original works of authorship which are made by Employee (solely or jointly with others) within the scope of and during
the period of Employee’s employment with the Company and which are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act. Employee understands and agrees that the decision
whether or not to commercialize or market any Invention developed by Employee solely or jointly with others is within the Company’s sole discretion and for the Company’s sole benefit and that no royalty will be due to Employee as a result
of the Company’s efforts to commercialize or market any such Invention. Employee acknowledges and agrees that nothing in this Agreement shall be deemed to grant, by implication, estoppel or otherwise, a license from the Company to me to make,
use, license, or transfer in any way an existing or future Invention. 
 (c) Inventions Assigned to the United
States. Employee agrees to assign to the United States government all Employee’s right, title, and interest in and to any and all Inventions whenever such full title is required to be in the United States by a contract between
the Company and the United States or any of its agencies. 

  
 2 

 (d) Maintenance of Records. Employee agrees to keep and maintain
adequate and current written records of all Inventions made by Employee (solely or jointly with others) during the term of Employee’s employment with the Company. The records will be in the form of notes, sketches, drawings, and any other
format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times. 

(e) Patent and Copyright Registrations. Employee agrees to assist the Company, or its designee, at the
Company’s expense, in every proper way to secure the Company’s rights in the Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, including the disclosure
to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for and obtain such
rights and in order to assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property
rights relating thereto. Employee further agrees that Employee’s obligation to execute or cause to be executed, when it is in Employee’s power to do so, any such instrument or papers shall continue after the termination of this Agreement.
If the Company is unable because of Employee’s mental or physical incapacity or for any other reason to secure Employee’s signature to apply for or to pursue any application for any United States or foreign patents or copyright
registrations covering Inventions or original works of authorship assigned to the Company as above, then Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Employee’s agent and
attorney in fact, to act for and in Employee’s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon
with the same legal force and effect as if executed by Employee. 
 (f) Exceptions. This Agreement does not obligate
Employee to assign to the Company any Invention that, in the sole judgment of the Company, reasonably exercised, is developed entirely on my own time and does not relate to the business efforts or research and development efforts in which, during
the period of my employment, the Company actually is engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company. However, Employee will also promptly disclose to the Company any
such Inventions for the purpose of determining whether they qualify for such exclusion. Employee understands that to the extent this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an
employee agreement to assign certain classes of inventions made by an employee, this Section 2 will be interpreted not to apply to any invention that a court rules and/or the Company agrees falls within such classes. 

  
 3 

	3.	 Former Employer Information. Employee agrees that Employee will not, during
Employee’s employment with the Company, improperly use or disclose any proprietary information or trade secrets of any former employer or other person or entity and that Employee will not bring onto the premises of the Company any unpublished
document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity. Employee further agrees that Employee will not incorporate into any Invention any Proprietary
Information or trade secrets of any former employer or other person or entity. 

  

	4.	 Conflicting Employment. Subject to the forgoing, Employee agrees that, during the term of
Employee’s employment with the Company, Employee will not engage in any other employment, occupation or consulting directly related to the Company’s business, nor will Employee engage in any other activities that conflict with
Employee’s obligations to the Company. 

  

	5.	 Non-Competition. 

(a) In order to protect the Company’s Proprietary Information and goodwill, during Employee’s employment and for a period of
(i) one (1) year following the date of the cessation of Employee’s employment with the Company (the “Last Date of Employment”) or such shorter period as the Company designates in writing to Employee (which designation must be
made no later than the date any waiver must be made under Section 5(b)(iii)), or (ii) two (2) years following the Last Date of Employment if Employee breaches his fiduciary duty to the Company or if Employee has unlawfully taken,
physically or electronically, property belonging to the Company (in either case, the “Restricted Period”), Employee shall not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee,
co-venturer or otherwise, anywhere in the world, engage or otherwise participate in any business that develops, manufactures or markets any products, performs any services, or conducts any research focused on using
T-cell therapy to address viruses or virus-related diseases (the “Noncompetition Restriction”). 

(b) Notwithstanding the foregoing, the Noncompetition Restrictions shall not apply: (i) if the Company terminates Employee’s employment
without “cause” (within the meaning of Mass. Gen. Laws Chapter 149, Sec 24L (c)); (ii) if the Employee has been laid off by the Company; (iii) if the Company waives the Noncompetition Restriction; or (iv) to Employee’s
activities on behalf of ElevateBio Management, Inc., or its subsidiaries and affiliates. 
 (c) In the event that the Non-Competition Restriction applies to Employee, the Company shall make garden leave payments to Employee for the post-employment portion of the Restricted Period (but for not more than 12 months following the end
of Employee’s employment) at the rate of 50% of the highest annualized base salary paid to Employee by the Company within the two-year period preceding the last day of Employee’s employment (the
“Garden Leave Pay”). Employee acknowledges and agrees that the Garden Leave Pay is consideration mutually agreed upon by the Company and Employee, and in exchange for Employee’s agreement to the Noncompetition Restriction. Employee
further acknowledges and agrees that any Garden Leave Pay he receives pursuant to this Agreement shall reduce (and shall not be in addition to) any severance or separation pay that Employee is otherwise entitled to receive from the Company pursuant
to any agreement, plan or otherwise. 

  
 4 

 (c) Employee acknowledges that this covenant in this Section 5 is necessary because the
Company’s legitimate business interests cannot be adequately protected solely by the other covenants in this Agreement. 
  

	6.	 Returning Company Documents. Employee agrees that, at the time of leaving
the Company, Employee will promptly deliver to the Company (and will not keep on a computer or otherwise in Employee’s possession, recreate or deliver to anyone else) any and all documents, records, data, notes, reports, proposals, lists,
correspondence, specifications, drawings, blueprints, sketches, materials, devices, equipment, other property, or reproductions of any aforementioned items developed by Employee pursuant to Employee’s employment with the Company or otherwise
belonging to the Company, its successors or assigns, including, without limitation, those records maintained pursuant to paragraph 2(d). In the event of the termination of Employee’s employment, Employee agrees to sign and deliver the
“Termination Certification” attached hereto as Exhibit 2. 

  

	7.	 Representations. Employee agrees to execute any proper oath or verify any proper document
required to carry out the terms of this Agreement. Employee represents that Employee’s performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by Employee in confidence
or in trust prior to Employee’s employment by the Company. Employee hereby represents and warrants that Employee has not entered into, and Employee will not enter into, any oral or written agreement in conflict herewith. 

 

	8.	 Restrictions on Solicitation. During any period in which Employee renders consulting
services to the Company and for a period of twelve (12) months thereafter, Employee shall not recruit or otherwise solicit, entice, induce or divert, or attempt to solicit, entice, induce or divert, any employees or customers of the Company, or
any of its subsidiaries or affiliates, to terminate their employment with, or otherwise cease their relationships with (as applicable), the Company or any of its subsidiaries or affiliates. 

 

	9.	 Remedies Upon Breach. Employee understands the restrictions in this Agreement are
necessary for the protection of the business and goodwill of the Company and Consultant considers them to be reasonable for such purpose. Any breach of this Agreement is likely to cause the Company substantial and irrevocable damage and therefore,
in the event of such breach, the Company, in addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief, without the posting of a bond. If Employee violates this Agreement, in
addition to all other remedies available to the Company at law, in equity, and under contract, Employee agrees that he is obligated to pay all the Company’s costs of enforcement of this Agreement, including reasonable attorneys’ fees and
expenses. 

  
 5 

	10.	 General Provisions. 

(a) Governing Law; Arbitration. This Agreement will be governed by the laws of the State of Delaware. Employee and the Company
agree to submit to mandatory binding arbitration, in New York, New York, any and all claims arising out of or related to this Agreement, except that each party may, at its or his option, seek injunctive relief in court in accordance with
Section 8 of this Agreement. EMPLOYEE AND THE COMPANY HEREBY WAIVE ANY RIGHTS TO TRIAL BY JURY IN REGARD TO SUCH CLAIMS. The arbitration shall be conducted through JAMS before a single neutral arbitrator, in accordance with the JAMS employment
arbitration rules then in effect. The arbitrator shall issue a written decision that contains the essential findings and conclusions on which the decision is based. 

(b) Entire Agreement. The Amended and Restated Executive Employment Agreement (the “Employment
Agreement”) to which this Agreement is attached, together with Prior Exhibits and the Equity Documents, as amended (both as defined in the Employment Agreement), set forth the entire agreement and understanding between the Company and Employee
relating to the subject matter herein and supersede all prior discussions or representations between us including, but not limited to, any representations made during Employee’s interview(s), whether written or oral. No modification of or
amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by the President of the Company and Employee. Any subsequent change or changes in Employee’s duties, or compensation will
not affect the validity or scope of this Agreement. Terms with initial capitalization that are not otherwise defined in this Restrictive Covenants Agreement have the meanings set forth in the Employment Agreement. 

(c) Enforcement. If one or more of the provisions in this Agreement are deemed void by law, then the remaining
provisions will continue in full force and effect. If any part of this Agreement is for any reason held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be
enforceable to the extent compatible with the applicable law as it shall then appear. 
 (d) Successors and Assigns.
This Agreement will be binding upon Employee’s heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns. 

(e) Notices. Any notices required or permitted hereunder shall be given to the appropriate party at the
party’s last known address. Such notice shall be deemed given upon personal delivery to the last known address or if sent by certified or registered mail, three days after the date of mailing. 

(f) Survival. The provisions of this Agreement shall survive the termination of Employee’s employment for any
reason and assignment of this Agreement by the Company to any successor in interest or other assignee. 

  
 6 

 (g) Headings. The headings to each section or paragraph of this
Agreement are provided for convenience of reference only and shall have no legal effect in the interpretation of the terms hereof. 

Employee has read this Restrictive Covenants Agreement and understand its terms. Employee has completely filled out Exhibit 1 to this
Agreement relating to Prior Inventions. 
 Employee understands that this agreement affects Employee’s rights to Inventions that
Employee makes during Employee’s employment with the Company, restricts Employee’s rights to disclose or use Proprietary Information and Third Party Information or subsequent to Employee’s period of employment, and prohibits Employee
from competing with the Company and from soliciting Company employees and Business Partners for one year after Employee’s employment is terminated for any reason. 

Employee further understands that by signing below, he certifies that he (i) was provided with this Agreement at least ten
(10) business days before the effective date of the Agreement and (ii) he has been advised by the Company that he has a right to consult with counsel prior to signing this agreement. 

Employee is executing this Agreement voluntarily. 

In witness whereof, the undersigned has executed this Agreement as a sealed instrument that shall become effective upon the later of
(i) the date this Agreement becomes fully executed by the parties or (ii) ten (10) business days after the Company provided Employee with this Agreement. 
  

									
	Employee	 		  		 		 	
					
	Signature:	 	 /s/ Vikas Sinha
	  		 	Date:	 	 10/2/2019

	Print Name:	 	Vikas Sinha	  		 		 	
	Address:	 		  		 		 	

  

									
	ACCEPTED AND AGREED TO:	  		 		 	
	 Allovir, Inc.
	  		 		 	
					
	Signature:	 	 /s/ David Hallal
	  		 	Date:	 	 10/2/2019

					
	Print Name:	 	David Hallal	  		 		 	
					
	Title:	 	Chief Executive Officer	  		 		 	

  
 7 

 EXHIBIT 1 

LIST OF PRIOR INVENTIONS 

AND ORIGINAL WORKS OF AUTHORSHIP 
 ☒
No inventions or improvements 
 ☐ Additional Sheets Attached 
  

			
	Signature of Employee:	 	 /s/Vikas Sinha

		
	Print Name of Employee:	 	Vikas Sinha

			
		
	Date:	 	 10/2/2019

  
 8 

 EXHIBIT 2 

TERMINATION CERTIFICATION 
 This is to
certify that Employee does not have on a computer or otherwise in Employee’s possession, nor has Employee failed to return, any documents, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints,
sketches, materials, devices, equipment, or other property, or reproductions of any aforementioned items belonging to Allovir, Inc., its subsidiaries, affiliates, successors or assigns (together, the “Company”). 

Employee further certify that Employee has complied with all the terms of the Company’s Restrictive Covenants Agreement signed by Employee, including the
reporting of any inventions and original works of authorship (as defined therein), conceived or made by Employee (solely or jointly with others) covered by that agreement. 

Employee further agrees that, in compliance with the Restrictive Covenants Agreement, Employee will preserve as confidential all trade secrets, confidential
knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of
authorship, customer lists, business plans, financial information or other subject matter pertaining to any business of the Company or any of its employees, clients, consultants or licensees. 

Employee further agrees that, for the applicable periods and as otherwise set forth in Restrictive Covenants Agreement, Employee will honor the restrictions
on Employee’s activities (directly or indirectly) as set forth therein. 
  

	
	Date:
	
	  

	Vikas Sinha

  
 9 

 EXHIBIT B 

SEPARATION AGREEMENT AND RELEASE 

  
 10EX-10.16

 Exhibit 10.16 

EXECUTIVE EMPLOYMENT AGREEMENT 

This Executive Employment Agreement (this “Agreement”) is entered in to between ViraCyte Inc.
(“Company”) and Agustin Melian (“Employee”). This Agreement is effective as of March, 21, 2019 (“Effective Date”). 

In consideration of the promises and the terms and conditions set forth in this Agreement, the parties agree as follows: 

1.    Position and Duties. As of a mutually agreeable start date the Company will
employ Employee as the Chief Medical Officer and Head of Global Medical Sciences of the Company. Employee will report to the Chief Executive Officer of the Company (the “CEO”) and will render such business and professional
services in the performance of his duties consistent with Employee’s position, as shall reasonably be assigned to him by the CEO or the Company’s Board of Directors (the “Board”). Employee’s employment shall
begin on the Effective Date. 
 2.    Service to the Company. Except as otherwise
specified herein, employee will be expected to devote his full working time and attention to the business of the Company, and will not render services to any other business without the prior approval of the Board or directly or indirectly, engage or
participate in any business that is competitive in any manner with the business of the Company; provided, however, that Employee may continue to serve on the boards of directors and advisory boards on which he presently serves, all of which have
been disclosed to the Company and may serve on additional boards (whether advisory or boards of directors) with the prior approval of the Board, not to be unreasonably withheld. The Company acknowledges that Employee is a party to a consulting
agreement with ElevateBio Management, Inc., (“ElevateBio”) and will devote a portion on of his working time to ElevateBio and its subsidiaries and affiliates. Employee will also be expected to comply with and be
bound by the Company’s operating policies procedures and practices that are from time to time in effect during the term of his employment and are provided to Employee. 

3.    At Will Employment. Employee and the Company understand and acknowledge that
Employee’s employment with the Company constitutes “at-will” employment, and the employment relationship may be terminated at any time with or without cause and with or without notice. 

4.    Compensation and Benefits. 

1.1.    Base Salary. While employed by the Company pursuant to this Agreement, the Company
shall pay the Employee an annual base salary of $435,000 (as adjusted from time to time in accordance with the terms hereof the (“Base Salary”), payable in accordance with the Company’s normal payroll
practices. The Board shall periodically review (at least annually) Employee’s Base Salary, provided that any changes thereto shall be determined by the Board in its sole and absolute discretion. Should ElevateBio terminate the consulting
agreement referenced in Section 4 for any reason other than for cause in consideration for the additional time Employee will devote to ViraCyte matters ViraCyte agrees to increase Employee’s salary in an amount equal to Employee’s
annual consulting payment not to exceed 25% of Employee’s then-current salary. 

  
 2 

 1.2.    Corporate Objectives Bonus.
Employee will be eligible to receive an annual cash bonus with a target bonus opportunity of 35% of Employee’s then current Base Salary (the “Target Annual Bonus”), upon the achievement of annual
corporate performance goals determined by the Board. Annual corporate performance goals shall be deter-mined no later than the end of January of the performance year, which generally shall be coincident with the calendar year. The Board at its sole
discretion, may increase Employee’s Annual Bonus or award an additional bonus to the Employee for extraordinary service to the Company. To receive payment of any bonus Employee must be employed by the Company at the time bonuses are paid. 

1.3    Employee Benefits. Employee shall be eligible to participate in all employee benefit
plans and arrangements, including, but not limited to, medical, dental vision and long-term disability insurance benefits and arrangements, as are made available by the Company to its other senior executives, subject to the terms and conditions
thereof. 
 1.4    Vacation. Employee will be entitled to paid vacation (in addition to
Company holidays) pursuant to the terms of the Company’s vacation policy as may exist from time to time. 
  

	 	5.	 Equity Matters. 

1.1.    Initial Award. Employee will be eligible to receive 791 843 shares of the common
stock of the Company (“Initial Award”), subject to the terms as set forth in the Company’s 2018 Equity Incentive Plan as well as Employee’s execution of the Viracyte Inc. Restricted Stock Agreement (the
“RSA”). 
 1.2.    Annual Award. Subject to approval
of the Board commencing on January 1, 2020, Employee will be eligible to receive an annual equity award in the form and amount determined by the Board or the Compensation Committee of the Board (the “Committee”) in a manner
consistent with the then prevailing practices of the Company’s industry. 

1.3.    Vesting. Pursuant to the terms of the RSA the Initial Award is subject to the
following vesting schedule: 25% of the shares shall vest on the 12-month anniversary of the vesting start date and an additional 6.25% of the shares shall vest on each
3-month anniversary of the Vesting Start Date thereafter. Notwithstanding the foregoing, in the event that there is a Sale Event (as that term is defined in the Viracyte, Inc. 2018 Equity Incentive
Plan) during the period of Recipient’s employment then all unvested equity awards held by Employee at the time of such Sale Event shall accelerate in vesting and as applicable become fully vested and exercisable and all stock options will
remain exercisable thereafter in accordance with the terms of the applicable award agreement. 

  
 3 

 Equity awards are also subject to accelerated vesting pursuant to the terms of Section 9 of this
Agreement. 
 6.    Expenses. The Company will, in accordance with applicable
Company policies and guidelines reimburse Employee for all reasonable and necessary expenses incurred by Employee in connection with his performance of services on behalf of the Company. 

7.    Inventions and Proprietary Information, Non-Competition. Employee hereby agrees
to execute the Company’s Proprietary Information and Inventions Assignment Agreement attached hereto as Exhibit A. 

8.    Definitions. 

1.1.    Cause. For purposes of this Agreement, “Cause” means
the occurrence of any of the following after the Effective Date (i) Employee’s persistent failure to carry out any material lawful duties of Employee or any lawful directions of the Chief Executive Officer reasonably consistent with
Employee’s duties; provided however, that Employee has been given reasonable notice of the specific failure and an opportunity to correct such failure within thirty (30) business days from the date of the notice (ii) Employee’s
conviction of or plea of nolo contendere to a felony, which has had or will have a detrimental effect on the Company’s reputation or business, (iii) Employee engaging in an act of gross negligence or willful misconduct in the performance
of his employment obligations and duties, (iv) Employee’s commission of an act of fraud against the Company or willful misappropriation of property belonging to the Company; (v) Employee engaging in any other willful misconduct that
has caused or will cause martial harm to the Company’s reputation or business; or (vi) Employee’s material breach of the Proprietary Information Inventions Assignment and Noncompete Agreement. No act or failure to act will be
considered ‘willful’ unless Employee has acted or failed to act, with a lack of good faith and with a lack of reasonable belief that Employee’s action or failure to act was in the best interest of the Company or any of its affiliates.

 1.2.    Disability. For purposes of this Agreement “Disability”
shall have that meaning set forth in Section 22(e)(3) of the Internal Revenue Code of 1986, as amended (the “Code”). 

1.3.    Good Reason. For purposes of this Agreement, “Good Reason”
means any of the following actions that have been taken by the Company without Employee s written consent, provided that (a) the Company receives, within ninety (90) days following Employee’s knowledge of the occurrence of any
of the conditions or events set forth in clauses(i) through (v) below, written notice from Employee specifying the specific basis for Employee s belief that Employee is entitled to terminate employment for Good Reason (b) the Company fails
to cure the condition or event constituting Good Reason within thirty (30) days after receipt of such written notice thereof, and (c) Employee terminates employment within thirty (30) days following expiration of such cure period:

 (i)     a material change, adverse to Employee, in Employee’s position titles, offices, reporting
relationship or duties; 

  
 4 

 (ii)    an assignment of any duties to Employee that are
inconsistent with any positions or offices held under this Agreement; 
 (iii)    a decrease in
Employee’s then current annual Base Salary other than a cumulative reduction of less than ten percent (10%) in connection with a general decrease in the salary of all other executive officers. 

(iv)    the relocation of Employee’s primary work location to a facility or a location that is more
than fifty (50) miles outside Boston, Massachusetts; or 
 (v)    the Company’s material breach
of this Agreement. 
 9.    Effect of Separation from Service. For purposes of this
Agreement no payment will be made to Employee upon termination of Employees employment unless such termination constitutes a “separation from service” within the meaning of
Section 409A of the Code, and Section 1.409A-l(h) of the regulations promulgated thereunder. 

1.1.    Separation for Cause, Death, Disability or Voluntary Separation from Service. In the
event of Employee’s separation from service from the Company for Cause or in the event of Employees death, Disability or voluntary separation from service at any time and for any reason, Employee or his estate will be paid only (i ) any earned
but unpaid Base Salary (ii) other unpaid vested amounts or benefits under the compensation, incentive and benefit plans of the Company in which Employee participates (including accrued vacation earned through his separation from service), and
(iii) reimbursement for all reason - able and necessary expenses incurred by Employee in connection with his performance of services on behalf of the Company in accordance with applicable Company policies and guidelines, in each case as of
the effective date of such separation from service (the “Accrued Compensation”). In the event of Employee’s death or Disability, any unvested stock option held by Employee shall be accelerated in vesting in
an amount equal to (i) twenty five percent (25%) plus (ii) five percent (5%) for each year of service to the Comp any of the total number of shares covered by the option. Employee or his estate will be allowed to exercise his vested stock
options to purchase the Company’s common stock if any during the time period set forth in, and in accordance with, the Company’s 2018 Equity Incentive Plan and governing stock option agreements. 

1.2.    Separation from Service without Cause or for Good Reason. In the event of Employees
separation from service from the Company without Cause or for Good Reason, and provided that Employee delvers to the Company a signed general release agreement in favor of the Company which shall contain provisions that are reasonable and customary
for such agreements and shall not contain any post-employment restrictive covenants, and satisfies all conditions to make the Release effective within sixty (60) days following Employee’s separation
from service, then, in addition to the Accrued Compensation Employee shall be entitled to the following: 
 (a) Lump sum
payment equal to twelve (12) months (the “Severance Period”) of the Employee’s then current Base Salary payable on the sixty-first (61st) day following the date of Employees separation from service.

  
 5 

 (b)    Lump sum payment for Target Annual Bonus payable
on the sixty-first (61st) day following the date of Employee’s separation from service; 

(c)    Provided Employee timely elects to continue health coverage under COBRA reimbursement for any
monthly COBRA premium payments made by Employee for Employee and his eligible dependents during the Severance Period; 

(d)    Notwithstanding the provisions of Section 5, all unvested and earned equity awards held by
Employee at the time of such separation from service shall accelerate in vesting and, as applicable become fully exercisable and all stock options will remain exercisable thereafter in accordance with the terms of the applicable award agreement.

 1.3.    Parachute Payments. In the event that any payments or benefits provided for in
this Agreement or otherwise payable to Employee (collectively the “Payments”) (i) constitute “parachute payments” within the meaning of Section 2800 of the Code and (ii) but for this Section,
would be subject to the excise tax imposed by Section 4999 of the Code then the Payments shall be payable either (i) in full, or (ii) as to such lesser amount which would result in no portion of the Payments being subject to the
excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by Employee on an after-tax basis, of the greatest amount of Payments, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. Any reduction to the Payments required
under this Section shall be made by the Company in its reasonable discretion in the following order and in a manner intended to comply with Section 409A of the Code (as determined by the Company): (i) payments that are payable in cash that are
valued at full value under Treasury Regulation Section 1.2800 -1 Q&A 24(a) will be reduced (if necessary, to zero) with amounts that are payable last reduced first; (ii) payments and benefits due in respect of any equity valued at full
value under Treasury Regulation Section 1.2800 -1, Q&A 24(a), with the highest values reduced first (as such values are determined under Treasury Regulation Section 1.2800-1, Q&A 24), will
next be reduced; (iii) payments that are pay - able in cash that are valued at less than full value under Treasury Regulation Section 1.2800-1, Q&A 24, with amounts that are payable last
reduced first, will next be reduced (iv) payments and benefits due in respect of any equity valued at less than full value under Treasury Regulation Section 1.2800-1, Q&A 24 with, the highest values reduced first (as such values are
determined under Treasury Regulation Section 1.2800 -1 Q&A 24), will next be reduced and (v) all other non-cash benefits not otherwise described in clauses (ii) or (iv) hereof will be next
reduced pro-rata. Any reductions made pursuant to each of clauses (i)-(v) of the immediately preceding sentence will be made in the following manner: first, a pro-rata
reduction of cash payment and payments and benefits due in respect of any equity not subject to Section 409A of the Code, and second, a pro-rata reduction of cash payments and payments and benefits due in respect of any equity subject to
Section 409A of the Code as deferred compensation. Unless the Company and Employee otherwise agree in writing, any determinations required under this Section shall be made in writing by the Company’s independent public accountants (the
“Accountants”), whose determinations shall be conclusive and binding upon Employee and the Company for all purposes. The Company shall cause the Accountants to provide its determinations and any supporting calculations with
respect to Employee to the Company and Employee. For purposes of making the calculations required by this Section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith
interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination
under this Section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section. 

  
 6 

 10.    Miscellaneous. 

1.1.    Arbitration. Employee and the Company agree to submit to mandatory binding
arbitration, in New York, New York any and all claims arising out of or related to this Agreement and Employee’s employment with the Company and the termination thereof, except that each party may, at its or his option, seek injunctive relief
in court related to the improper use disclosure or misappropriation of a party’s proprietary, confidential or trade secret information. EMPLOYEE AND THE COMPANY HEREBY WAIVE ANY RIGHTS TO TRIAL BY JURY IN REGARD TO SUCH CLAIMS. This Agreement
to arbitrate does not restrict Employee’s right to file administrative claims Employee may bring before any government agency where, as a matter of law, the parties may not restrict Employee’s ability to file such claims (including, but
not limited to, the National Labor Relations Board, the Equal Employment Opportunity Commission and the Department of Labor). However, Employee and the Company agree that, to the fullest extent permitted by law arbitration shall be the exclusive
remedy for the subject matter of such administrative claims. The arbitration shall be conducted through JAMS before a single neutral arbitrator in accordance with the JAMS employment arbitration rules then in effect. The arbitrator shall issue a
written decision that contains the essential: findings and conclusions on which the decision is based. 

1.2.    Indemnification. The Company shall indemnify Employee with respect to activities in
connection with his employment hereunder to the fullest extent provided in the Company’s bylaws. Employee will be named as an insured on the director and officer liability insurance policy currently maintained, or as may be maintained by the
Company from time to time, and, in addition, Employee will enter into the form of indemnification agreement provided to other similarly situated executive officers and directors of the Company. 

1.3.    Section 409A. To the extent (a) any payments or benefits to which Employee
becomes entitled under this Agreement or welder any agreement or plan referenced herein, in connection with Employee’s termination of employment with the Company constitute deferred compensation subject to Section 409A of the Code and
(b) Employee is deemed at the time of such termination of employment to be a “specified employee” under Section 409A of the Code then such payments shall not be made or commence until the earliest of (i) the
expiration of the six (6)-month period measured from the date of Employee’s “separation from service” (as such term is at the time defined in Treasury Regulations under Section 409A of the Code) from the Company or
(ii) the date of Employee’s death following such separation from service; provided however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to Employee, including (without limitation) the
additional twenty percent (20%) tax for which Employee would otherwise be liable under Section 409A(a)(l)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable deferral period any payments which would have
otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to Employee or Employee’s beneficiary in one lump sum (without interest). Any termination of Employee’s
employment is intended to constitute a “separation from service” and will be determined consistent with the rules relating to a “separation from service” as such term is defined in Treasury
Regulation Section 1.409A-l. It is intended that each installment of the payments provided hereunder constitute separate “payments” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). It is further intended that payments hereunder satisfy to the greatest extent possible, the exemption from the application of Section 409A of the Code (and any state law of
similar effect) provided under Treasury Regulation Section 1.409A-I (b)(4) (as a “short-term deferral”). To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision will be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Except as otherwise expressly
provided herein, to the extent any expense reimbursement or the provision of any in-kind benefit under this Agreement is determined to be subject to Section 409A of the Code, the amount of any such expenses eligible for reimbursement, or the
provision of any in-kind benefit in one calendar year shall not affect the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to
medical expenses), in no event shall any expenses be reimbursed after the last day of the calendar year following the calendar year in which Employee incurred such expenses, and in no event shall any right to reimbursement or the provision of any
in-kind benefit be subject to liquidation or exchange for another benefit. 

  
 7 

 1.4.    Severability. If any provision of
this Agreement shall be found by any arbitrator or court of competent jurisdiction to be in valid or unenforceable, then the parties hereby waive such provision to the extent of its invalidity or unenforceability, and agree that all other provisions
in this Agreement shall continue in full force and effect. 
 1.5.    No Waiver. The
failure by either party at any time to require performance or compliance by the other of any of its obligations or agreements shall in no way affect the right to require such performance or compliance at any time thereafter. The waiver by either
party of a breach of any provision hereof shall not be taken or held to be a waiver of any preceding or succeeding breach of such provision or as a waiver of the provision itself. No waiver of any kind shall be effective or binding unless it is in
writing and is signed by the party against whom such waiver is sought to be enforced. 

1.6.    Assignment. This Agreement and all rights hereunder are personal to Employee and may
not be transferred or assigned by Employee at any time. The Company may assign its rights together with its obligations hereunder to any purchaser of all or substantially all of its business and assets, provided however, that any such assignee
assumes the Company’s obligations hereunder. 

  
 8 

 1.7.    Withholding. All sums payable to
Employee hereunder shall be in United States Dollars and shall be reduced by all federal state, local and other withholding and similar taxes and payments required by applicable law. 

1.8.    Entire Agreement. This Agreement (and the exhibit(s) hereto) constitutes the entire
and only agreement and understanding between the parties relating to Employee’s employment with Company. This Agreement supersedes and cancels any and all previous contracts arrangements or understandings with respect to Employee’s
employment. 
 1.9.    Amendment. The parties understand and agree that this Agreement may
not be amended, modified or waived, in whole or in part, except in a writing executed by Employee and the Company. 

1.10.    Notices. All notices i f any, and all other communications if any required or
permitted under this Agreement shall be in writing and hand delivered, sent via facsimile, sent by registered first class mail, postage pre-paid or sent by nationally recognized express courier service. Such
notices and other communications shall be effective upon receipt if hand delivered or sent via facsimile, five (5) days after mailing if sent by mail, and one (l) day after dispatch if sent by express courier, to the following addresses,
or such other addresses as any party shall notify the other parties: 
  

	 	If to the Company:	 ViraCyte Inc. 

	 	    	 2925 Richmond Ave, Suite 1274 

	 	    	 Houston, Texas 77098 

	 	    	 Attention: Chairman Board Compensation Committee 

 

	 	With a copy to:	 Pillsbury Winthrop Shaw Pittman LLP 

	 	    	 909 Fannin, Suite 2000 

	 	    	 Houston, Texas 77010 

	 	    	 Attn: Andrew L. Strong 

 

	 	If to Employee:	 The last address on file in the Company s records. 

1.11.    Binding Nature. This Agreement shall be binding upon, and inure to the benefit of,
the successors and personal representatives of the respective parties here to. 

1.12.    Counterparts. This Agreement may be executed in two or more counterparts each of
which shall be deemed to be an original but all of which taken together constitute one and the same agreement. 

1.13.    Governing Law. This Agreement and the rights and obligations of the par-ties hereto
shall be construed in accordance with the laws of the Commonwealth of Massachusetts, without giving effect to the principles of conflict of laws. 

1.14.    Attorneys’ Fees. In the event of any claim, demand or suit arising out of or
with respect to this Agreement the prevailing party shall be entitled to reasonable costs and attorneys’ fees, including any such costs and fees upon appeal. 

  
 9 

 IN WITNESS WHEREOF the Company and Employee have executed this Agreement as
of the date first above written. 
 VIRACYTE, INC. 
  

									
	 /s/ David Hallal
	 	                	 	 /s/ Agustin Melian

					
	Name:	 	 David Hallal
	 		 	Name:	 	 Agustin Melian

 Its: Chairman and CEO 

  
 1 

 EXHIBIT A 

EMPLOYEE INVENTION ASSIGNMENT 

AND CONFIDENTIALITY AGREEMENT 

  
 1 

 PROPRIETARY INFORMATION 

INVENTION ASSIGNMENT AGREEMENT 

As a condition of the employment of Agustin Melian (“Employee”) with ViraCyte, Inc. its subsidiaries affiliates,
successors or assigns (together the “Company”), and in consideration of Employee’s engagement in any capacity with the Company and Employee’s receipt of the compensation now and hereafter paid to Employee by the Company,
Employee will execute this Proprietary Information and Invention Assignment Agreement (this “Agreement”), and agrees to the following: 
  

	1.	 Proprietary Information. 

(a)     Company Information. Employee agrees at all times during the term of Employee’s employment and
thereafter, to hold in strictest confidence and not to use, except for the benefit of the Company or to disclose to any person, firm or corporation without written authorization of the Board of Directors of the Company, any Proprietary Information
of the Company, except under a nondisclosure agreement duly authorized and executed by the Comp any. Employee understands that “Proprietary Information” means any non-public information regarding or
relating to the Company or its products including: (1) the actual or anticipated business or research and development of the Company technical data, trade secrets or know-how, including, but not limited
to, research product plans or other information regarding the Company’s products or services and markets therefore (2) research, clinical or other trials, developments, inventions, processes, formulas, technology, designs, drawings,
engineering, software, hardware configuration information, marketing, finances or other business information; (3) customer lists and customers (including, but not limited to, customers of the Company on whom Employee called or with whom
Employee became acquainted during the term of Employee’s employment); (4) the identity skills and compensation of employees, consultants or contractors; (5) policies and procedures of the Company; (6) anything related to Company Inventions
(as defined herein) and (7) Third Party Information (as defined herein). Employee further understands that Proprietary Information does not include any of the foregoing items which have become publicly known and made generally available through
no wrongful act of the Employee or of others who were under confidentiality obligations as to the item or items involved or improvements or new versions thereof. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section l 833(b), Employee shall
not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an
attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a laws suit or other proceeding if such filing is made under seal. In addition
notwithstanding the foregoing, Employee shall not be prohibited from disclosing Proprietary Information to a government agency as a whistleblower. 

(b)    Third Party Information. Employee recognizes that the Company has received and in the future
will receive from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes (“Third Party
Information”). Employee agrees to hold all Third Party Information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out Employee’s work for the Company
consistent with the Company’s agreement with such third party. 

	2.	 Inventions. 

(a)    Inventions Retained and Licensed. Employee has attached hereto, as Exhibit I, a list describing
all inventions original works of authorship, developments, improvements, and trade secrets which were made by Employee prior to Employee’s employment with the Company (collectively referred to as “Prior Inventions”), which belong to
Employee which relate to the Company’s proposed business, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, Employee represents that there are no such Prior In vent ions.
If in the course of Employee’s employment with the Company Employee incorporates into a Company product, process or service a Prior Invention owned by Employee or in which Employee has an interest Employee hereby grants to the Company a
nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual worldwide license to make, have made modify use and sell such Prior Invention as part of or in
connection with such product, process or service and to practice any method related thereto. 
 (b)    Assignment
of Inventions. Employee agrees that Employee will promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby assign (or, for future inventions agree to assign) to the
Company, or its designee, all Employee’s right, title, and interest in and to any and all inventions original works of authorship, writings, developments, concepts, improvements, designs, discoveries, ideas processes formulas, data, trademarks
or trade secrets, whether or not patentable or registrable under copyright or similar laws, which Employee may solely or jointly conceive or develop or reduce to practice within the scope of Employee’s employment or cause to be conceived or
developed or reduced to practice, during the period of time Employee is employed by the Company (collectively referred to as “Inventions”) except as provided in Section 3(f) below. Employee agrees that Company will exclusively own all
work product that is made by Employee (solely or jointly with others) within the scope of Employee’s employment. Employee further acknowledges that all original works of authorship which are made by Employee (solely or jointly with others)
within the scope of and during the period of Employee’s employment with the Company and which are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act. Employee understands and
agrees that the decision whether or not to commercialize or market any Invention developed by Employee solely or jointly with others is within the Company’s sole discretion and for the Company’s sole benefit and that no royalty will be due
to Employee as a result of the Company’s efforts to commercialize or market any such Invention. Employee acknowledges and agrees that nothing in this Agreement shall be deemed to grant by implication estoppel or otherwise, a license from the
Company to me to make use, license or transfer in any way an existing or future Invention. 

 (c)    Inventions Assigned to the United States.
Employee agrees 10 assign to the United States government all Employee’s right, title, and interest in and to any and all Inventions whenever such full title is required to be in the United States by a contract between the Company and the
United States or any of its agencies. 
 (d)    Maintenance of Records. Employee agrees to keep and
maintain adequate and current written records of all Inventions made by Employee (solely or jointly with others) during the term of Employee’s employment with the Company. The records will be in the form of notes, sketches drawings, and any
other format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times. 

(e)    Patent and Copyright Registrations. Employee agrees to assist the Company, or its designee, at the
Company’s expense in every proper way to secure the Company’s rights in the Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, including the disclosure
to the Company of all pertinent information and data with respect thereto the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for and obtain such
rights and in order to assign and convey to the Company, its successors, assigns and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property
rights relating thereto. Employee further agrees that Employee’s obligation to execute or cause to be executed, when it is in Employee’s power to do so, any such instrument or papers shall continue after the termination of this Agreement.
If the Company is unable because of Employee s mental or physical incapacity or for any other reason to secure Employee’s signature to apply for or to pursue any application for any United States or foreign patents or copyright registrations
covering Inventions or original works of authorship assigned to the Company as above, then Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Employee’s agent and attorney in fact, to
act for and in Employees behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon with the same legal force
and effect as if executed by Employee. 
  

	3.	 Former Employer Information. Employee agrees that Employee will not, during
Employee’s employment with the Company, improperly use or disclose any proprietary information or trade secrets of any former employer or other person or entity and that Employee will not bring onto the premises of the Company any unpublished
document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer person or entity. Employee further agrees that Employee will not in-corporate into any Invention any Proprietary
Information or trade secrets of any former employer or other person or entity. 

  

	4.	 Conflicting Employment. Subject to the forgoing, Employee agrees that, during the term of
Employee’s employment with the Company Employee will not engage in any other employment occupation or consulting directly related to the Company’s business, nor will Employee engage in any other activities that conflict with Employees
obligations to the Company. 

	5.	 Returning Company Documents. Employee agrees that, at the time of leaving the Company, Employee
will promptly deliver to the Company (and will not keep on a computer or otherwise in Employee’s possession, recreate or deliver to anyone else) any and all documents, records, data notes, reports, proposals lists, correspondence,
specifications drawings blueprints sketches, materials devices equipment other property or reproductions of any aforementioned items developed by Employee pursuant to Employee’s employment with the Company or otherwise belonging to the Company,
its successors or assigns, including, without limitation, those records maintained pursuant to paragraph 2(d). In the event of the termination of Employee’s employment, Employee agrees to sign and deliver the “Termination
Certification” attached hereto as Exhibit 2. 

  

	6.	 Representations. Employee agrees to execute any proper oath or verify any proper document
required to carry out the terms of this Agreement. Employee represents that Employee’s performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by Employee in confidence
or in trust prior to Employees employment by the Company. Employee hereby represents and warrants that Employee has not entered into, and Employee will not enter into, any oral or written agreement in conflict herewith. 

 

	7.	 General Provisions. 

1.15. Governing Law; Arbitration. This Agreement will be governed by the laws of the Commonwealth of Massachusetts.
Employee and the Company agree to submit to mandatory binding arbitration in New York, New York any and all claims arising out of or related to this Agreement, except that each party may, at its or his option, seek injunctive relief in court related
to the improper use, disclosure or misappropriation of a party’s proprietary confidential or trade secret information. EMPLOYEE AND THE COMPANY HEREBY WAIVE ANY RIGHTS TO TRIAL BY JURY IN REGARD TO SUCH CLAIMS. The arbitration shall be
conducted through JAMS before a single neutral arbitrator in accordance with the JAMS employment arbitration rules then in effect. The arbitrator shall issue a written decision that contains the essential findings and conclusions on which the
decision is based. 
 (a)     Entire Agreement. This Agreement, along with any application Employee has
submitted to the Company if any, and any executed Employment Agreement Employee has with the Company, if any, sets forth the entire agreement and understanding between the Company and Employee relating to the subject matter herein and supersedes all
prior discussions or representations between us including, but not limited to any representations made during Employee’s interview(s), whether written or oral. No modification of or amendment to this Agreement, nor any waiver of any rights
under this Agreement will be effective unless in writing signed by the President of the Company and Employee. Any subsequent change or changes in Employee’s duties or compensation will not affect the validity or scope of this Agreement. 

 (b)    Severability.    If one
or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full force and effect. 

(c)    Successors and Assigns. This Agreement will be binding upon Employees heirs, executors, administrators
and other legal representatives and will be for the benefit of the Company, its successors, and its assigns. 

(d)    Notices. Any notices required or permitted hereunder shall be given to the appropriate party at the
party’s last known address. Such notice shall be deemed given upon personal delivery to the last known address or if sent by certified or registered mail three days after the date of mailing. 

(e)    Survival. The provisions of this Agreement shall survive the termination of Employee’s employment
for any reason and assignment of this Agreement by the Company to any successor in interest or other assignee. 

(f)    Headings. The headings to each section or paragraph of this Agreement are provided for convenience of
reference only and shall have no legal effect in the interpretation of the terms hereof 
 Employee has read this Proprietary
Information, And Invention Assignment Agreement and understand its terms. Employee has completely filled out Exhibit 1 to this Agreement relating to Prior Inventions. 

This agreement shall be effective as of the date of Employees execution of this this Proprietary Information, And Invention Assignment Agreement. 

Employee understands that this agreement affects Employee’s rights to Inventions that Employee makes during Employee’s employment
with the Company, restricts Employee’s rights to disclose or use Proprietary Information and Third Party Information or subsequent to Employee’s period of employment, and prohibits Employee from competing with the Company and from
soliciting Company employees and Business Partners for one year after Employee’s employment is terminated for any reason. 
 Employee 

Signature: /s/ Agustin Melian                    

 ACCEPTED AND AGREED TO: 
 ViraCyte, Inc. 

Signature: /s/ David Hallal 
 Name: David Hallal 

 Title: Chairman and CEO 

Date: March 21, 2019                     

 EXHIBIT 1 

LIST OF PRIOR INVENTIONS 

AND ORIGINAL WORKS OF AUTHORSHIP 
 ☒
No inventions or improvements 
 ☐ Additional Sheets Attached 

Signature of Employee:              /s/Agustin Melian 

Print Name of Employee: Agustin Melian 

Date:                March 21,
2019             

 EXHIBIT 2 

TERMINATION CERTIFICATION 
 This is to
certify that Employee does not have on a computer or otherwise in Employee’s possession, nor has Employee failed to return, any documents, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints,
sketches, materials, devices, equipment, or other property, or reproductions of any aforementioned items belonging to ViracCyte, Inc., its subsidiaries, affiliates, successors or assigns (together, the “Company”). 

Employee further certify that Employee has complied with all the terms of the Company’s Restrictive Covenants Agreement signed by Employee, including the
reporting of any inventions and original works of authorship (as defined therein), conceived or made by Employee (solely or jointly with others) covered by that agreement. 

Employee further agrees that, in compliance with the Restrictive Covenants Agreement, Employee will preserve as confidential all trade secrets, confidential
knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of
authorship, customer lists, business plans, financial information or other subject matter pertaining to any business of the Company or any of its employees, clients, consultants or licensees. 

Employee further agrees that, for the applicable periods and as otherwise set forth in Restrictive Covenants Agreement, Employee will honor the restrictions
on Employee’s activities (directly or indirectly) as set forth therein. 
 Date: 

 
     
                                         
                                         
           
 Agustin Melian

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]